Cx Precision Medicine—a diagnostics company founded on research by Dr. Sid O’Bryant at UNT Health Science Center at Fort Worth—spun out from HSC to advance O’Bryant’s pioneering work on blood-based biomarkers for Alzheimer’s disease and other neurodegenerative conditions. The company recently gained higher visibility—and an even greater opportunity for impact—by being selected to join the prestigious StartUp Health’s Alzheimer’s Moonshot community.
Taking part in that “Moonshot” reinforces both CxPM and HSC’s place “at the forefront of the global effort to drive innovation in Alzheimer’s care and diagnostics,” HSC said in announcing the selection.
Research by CxPM Founder O’Bryant, who’s also a professor of family medicine at HSC and executive director of HSC’s Institute for Translational Research, is the driving force behind CxPM’s mission of improving early detection and treatment strategies for Alzheimer’s.
“I’m excited and humbled by the achievement of the CxPM team,” O’Bryant said in a statement. “I embarked on this journey of creating a blood test for Alzheimer’s detection in primary care because of my own clinical and personal experiences. I’m thrilled to see this soon come to fruition in clinics.”
Post-spinout, HSC has continued a collaborative relationship with CxPM via sponsored research activities, representation on the CxPM board, and “prosecution of patent applications in a strong, global intellectual property portfolio,” HSC said.
Impact of the Moonshot
New York-based StartUp Health Alzheimer’s Moonshot initiative is dedicated to advancing solutions to prevent, diagnose, and cure Alzheimer’s, a disease affecting more than 55 million people worldwide.
Joining the Alzheimer’s Moonshot community “marks a significant milestone” in CxPM’s journey, HSC said. The company is currently seeking to expand its operations and raise additional capital—goals that could be impacted positively by this new milestone. HSC said the Moonshot program offers “invaluable access to a network of investors, collaborators, and strategic partners.”
“We’re deeply honored to be a part of the Alzheimer’s Moonshot initiative,” CxPM CEO Danguole Altman said in a statement. “The collaboration between Cx Precision Medicine and HSC has been instrumental in bringing precision diagnostics to Alzheimer’s care. This will enable us to enhance our real-world impact on patients’ lives.”
As part of the Moonshot community, CxPM will now gain access to mentorship, global collaborations, and the opportunity to enhance its impact through partnerships with other innovators focused on Alzheimer’s care.
The achievement “highlights the role of academic research and innovation in addressing one of the world’s most challenging diseases,” HSC said, and positions CxPM “as a leader in precision diagnostics for Alzheimer’s disease.”
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.